Investigation of Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma at Hochiminh City Oncology Hospital

Abstract

Abstract Introduction Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy. These areforms of follicular cell-derived tumors, and they have the capacity to catch iodine. The overall survival rates of metastatic or progressive differentiated thyroid carcinomaat 10 and 15years were 56% and 45% in cases of the radioiodine-avid tumor. The rates were only 10% and 6%at 10and 15 years respectively if the tumor becamenon-iodine avid.Identification ofthe iodine-refractorycriteria helps us treat properly. Patients and Methods a retrospective, cross-sectional descriptive analysis of radioactive iodine-refractory DTC conducted from January 2017 to December 2017. Data Processing and Analysis with SPSS 22.0 Results Forty-three in 1428 patients enrolled in the study from January 2017 to December 2017. About 50% of patients were T3-and T4 tumor,48.8% got N1b lymph nodes metastasis. Distal accounted for 50%, in which pulmonary, bone metastasis, and both were 66.7%, 23.8%, and 9.5%, respectively. The refractory rate was 3.0%, in which most of them belonged to group III (44.2%). Treatment followed by operation (11.6%), external radiotherapy ( 20.9%) and the others were followed up actively or treated Levothyroxinsuppression therapy and further radioactive iodine, aiming to palliative care and reduction of tumor burden.No patient administrated TKIstherapy. Conclusions The most of the refractory patients were elder and under the high-risk group of recurrence, in which mainly T4 tumor or locoregional invasion or distant metastasis. Identification of radioactive iodine-refractory criteria helps us treat properly. TKIs therapy in case of progression administrated recently.